HLB Innovation Posts Operating Loss of 10.4B Won in Q1, Semiconductor Unit Profitable

Consolidated revenue 9.45B won, operating loss 10.4B won, net loss 10.4B won (loss widened)
Standalone: revenue 9.4B won, operating profit 0.17B won, net profit 0.12B won (semiconductor profitable)
Biotech subsidiary Verismo Therapeutics: revenue 0.5B won, net loss 104.4B won (CAR-T clinical trials ongoing)
Consolidated R&D cost 8B won (85% of revenue), heavy biotech investment
Debt ratio 16%, cash equivalents 24.2B won, convertible bonds 22.3B won (adequate liquidity)
Stock split (5:1) approved; shares increased by 6.07M due to CB conversion (end: 150.7M shares)
No share buyback, cancellation, or dividend